Please select the option that best describes you:
Would you offer adjuvant HER 2 directed therapy for ER+/PR+/HER2+ pT1-T2 N0 papillary carcinoma of the breast?
It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.
Answer from: Medical Oncologist at Academic Institution
While there is consensus that invasive papillary (not micropapillary) cancer of the breast carries a better prognosis, long-term data with conventional therapies are not available to reliably determine the recurrence and mortality risks relative to more common subtypes. I would therefore use size, g...
Sign in or Register to read more